Pressure Bio Seeks to Raise $5M in Direct Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Pressure BioSciences has filed with US regulators for a direct offering of a maximum of $5 million of its Series F preferred stock.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission on Friday, Pressure Bio said it plans to offer 5,000 shares of its Series F preferred stock at $1,000 per share. The stock is being offered directly to one or more accredited investors.

Moody Capital Solutions is acting as placement agent on the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.